Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Cedars-Sinai Medical Center
hospital in Los Angeles, California, United States
Related events
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.